We are live on ! Find out more
EAM

Eventide Asset Management Portfolio holdings

AUM $7.48B
1-Year Est. Return 104.76%
This Fund
S&P 500
This Quarter Est. Return
+8.65%
1 Year Est. Return
+104.76%
3 Year Est. Return
+313.12%
5 Year Est. Return
+388.67%
10 Year Est. Return
+3,437.54%
AUM
$7.44B
AUM Growth
+$696M
Cap. Flow
+$296M
Cap. Flow %
3.98%
Top 10 Hldgs %
25.63%
Holding
169
New
15
Increased
63
Reduced
24
Closed
17

Top Buys

Rank Stock Value
1
ZYME icon
Zymeworks
ZYME
+$57.2M
2
NCNO icon
nCino
NCNO
+$41.7M
3
VECT
VectivBio Holding AG Ordinary Shares
VECT
+$35.5M
4
ARGX icon
argenx
ARGX
+$33.8M
5
SHLS icon
Shoals Technologies Group
SHLS
+$31.8M

Top Sells

Rank Stock Value
1
SRPT icon
Sarepta Therapeutics
SRPT
+$52M
2
VRSK icon
Verisk Analytics
VRSK
+$37.6M
3
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
+$26.1M
4
SNDX icon
Syndax Pharmaceuticals
SNDX
+$24.1M
5
OKTA icon
Okta
OKTA
+$23.8M

Sector Composition

Rank Sector Weight
1 Healthcare 37.34%
2 Technology 29.25%
3 Industrials 12.31%
4 Consumer Discretionary 7.52%
5 Communication Services 5.3%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SMAR
51
DELISTED
Smartsheet Inc.
SMAR
$50.3M 0.68%
696,131
+259,131
+59% +$16.2M
MAX icon
52
MediaAlpha
MAX
$607M
$50.1M 0.67%
1,190,612
+156,053
+15% +$6.24M
BEP icon
53
Brookfield Renewable
BEP
$8.65B
$47.7M 0.64%
1,236,000
– –
TPTX
54
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
$45.1M 0.61%
578,000
+73,000
+14% +$5.39M
STRO icon
55
Sutro Biopharma
STRO
$275M
$44.1M 0.59%
237,098
– –
BBIO icon
56
BridgeBio Pharma
BBIO
$13.4B
$43.4M 0.58%
712,197
– –
BPMC
57
DELISTED
Blueprint Medicines
BPMC
$40.6M 0.55%
461,712
-288
-0.1% -$26.4K
NCNO icon
58
nCino
NCNO
$2.32B
$39.7M 0.53%
+662,500
New +$41.7M
HASI icon
59
Hannon Armstrong Sustainable Infrastructure Capital
HASI
$4.68B
$39.3M 0.53%
700,200
– –
BEPC icon
60
Brookfield Renewable
BEPC
$5.39B
$38.1M 0.51%
908,919
-69,438
-7% -$2.95M
NOVT icon
61
Novanta
NOVT
$5.23B
$37.7M 0.51%
280,000
– –
VRSK icon
62
Verisk Analytics
VRSK
$23.4B
$37.2M 0.5%
213,000
-211,800
-50% -$37.6M
CGEM icon
63
Cullinan Oncology
CGEM
$1.32B
$36.2M 0.49%
1,440,145
+227,590
+19% +$7M
IMVT icon
64
Immunovant
IMVT
$7.57B
$35.6M 0.48%
3,370,994
+897,994
+36% +$12.5M
BCYC
65
Bicycle Therapeutics
BCYC
$257M
$35.3M 0.47%
1,163,471
+751,633
+183% +$22.7M
CWEN icon
66
Clearway Energy Class C
CWEN
$6.14B
$34.5M 0.46%
1,303,400
– –
ALLK
67
DELISTED
Allakos
ALLK
$34.2M 0.46%
401,000
+84,000
+26% +$8.39M
LII icon
68
Lennox International
LII
$12.5B
$33.3M 0.45%
95,000
– –
MDB icon
69
MongoDB
MDB
$30.4B
$32.3M 0.43%
89,355
+375
+0.4% +$116K
ADCT icon
70
ADC Therapeutics
ADCT
$139M
$31.9M 0.43%
1,311,990
+397,251
+43% +$9.22M
NRIX icon
71
Nurix Therapeutics
NRIX
$2.58B
$31.8M 0.43%
1,200,000
– –
XPO icon
72
XPO
XPO
$20.9B
$30.8M 0.41%
636,107
– –
CGNX icon
73
Cognex
CGNX
$9.95B
$30.2M 0.41%
359,000
– –
MPWR icon
74
Monolithic Power Systems
MPWR
$56.1B
$28.9M 0.39%
77,459
+3,300
+4% +$1.16M
SWKS icon
75
Skyworks Solutions
SWKS
$13.5B
$28.4M 0.38%
148,047
+500
+0.3% +$88.7K
1 2
3
4 5

Similar funds

S
SignatureFD Atlanta, Georgia $7.49B AUM 24.82% 1-Year Est. Return
CCM
Check Capital Management Costa Mesa, California $7.52B AUM 15.3% 1-Year Est. Return
O
Ossiam Paris, France $7.54B AUM 50.81% 1-Year Est. Return
HI
Harbour Investments Madison, Wisconsin $7.43B AUM 24.49% 1-Year Est. Return
HPC
HM Payson & Co Portland, Maine $7.54B AUM 31.34% 1-Year Est. Return
FPP
Findlay Park Partners London, United Kingdom $7.41B AUM 26.32% 1-Year Est. Return
RIG
RiverFront Investment Group Richmond, Virginia $7.56B AUM 23.82% 1-Year Est. Return
TAM
Tocqueville Asset Management New York $7.56B AUM 44.87% 1-Year Est. Return

Eventide Asset Management's Q2 2021 Portfolio in Review

As of Q2 2021, Eventide Asset Management held 169 positions worth $7.44B, up 10% from $6.75B the previous quarter. Its ten largest holdings account for 26% of the portfolio.

Eventide Asset Management deployed $296M of net new capital in Q2 2021, opening 15 new positions and adding to 63 existing holdings. Its largest new stake was nCino: 662,500 shares worth $39.7M.

By sector, the portfolio is most concentrated in Healthcare at 37% of assets, down from 42% a quarter earlier, followed by Technology and Industrials.

On the sell side, the largest reduction was Verisk Analytics, an estimated $37.6M trimmed.

  • Eventide Asset Management's largest Q2 2021 buy was nCino: 662,500 shares worth $39.7M.
  • Eventide Asset Management added most to Zymeworks in Q2 2021, an estimated $57.2M increase.
  • Eventide Asset Management's biggest Q2 2021 reduction was Verisk Analytics, cutting an estimated $37.6M.
  • Eventide Asset Management fully exited Sarepta Therapeutics in Q2 2021, selling an estimated $52M.
  • Eventide Asset Management's ten largest holdings make up 26% of its $7.44B portfolio in Q2 2021.
  • Eventide Asset Management opened 15 new positions and closed 17 in Q2 2021.
  • Eventide Asset Management's portfolio value rose 10% quarter-over-quarter to $7.44B.

Based on Eventide Asset Management's 13F filing for Q2 2021, filed 16 Aug 2021.